ARQT - Arcutis Biotherapeutics appoints CFO
2024-04-10 08:16:17 ET
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript
- Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
- Arcutis announces pricing of $150 million public offering
- Arcutis licenses Japanese rights for Zoryve to Sato Pharmaceutical
- Seeking Alpha’s Quant Rating on Arcutis Biotherapeutics